These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 34986523)

  • 1. Treatment patterns and survival in advanced unresectable esophageal squamous cell cancer: A population-based study.
    Pape M; Vissers PAJ; de Vos-Geelen J; Hulshof MCCM; Gisbertz SS; Jeene PM; van Laarhoven HWM; Verhoeven RHA
    Cancer Sci; 2022 Mar; 113(3):1038-1046. PubMed ID: 34986523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognosis of Interval Distant Metastases After Neoadjuvant Chemoradiotherapy for Esophageal Cancer.
    Kroese TE; Dijksterhuis WPM; van Rossum PSN; Verhoeven RHA; Mook S; Haj Mohammad N; Hulshof MCCM; van Berge Henegouwen MI; van Oijen MGH; Ruurda JP; van Laarhoven HWM; van Hillegersberg R
    Ann Thorac Surg; 2022 Feb; 113(2):482-490. PubMed ID: 33610543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Implications of Conversion Surgery After Induction Therapy for T4b Thoracic Esophageal Squamous Cell Carcinoma.
    Miyata H; Sugimura K; Motoori M; Omori T; Yamamoto K; Yanagimoto Y; Shinno N; Yasui M; Takahashi H; Wada H; Ohue M; Yano M
    Ann Surg Oncol; 2019 Dec; 26(13):4737-4743. PubMed ID: 31414291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma.
    Bando H; Kotani D; Tsushima T; Hara H; Kadowaki S; Kato K; Chin K; Yamaguchi K; Kageyama SI; Hojo H; Nakamura M; Tachibana H; Wakabayashi M; Fukutani M; Togashi Y; Fuse N; Nishikawa H; Kojima T
    BMC Cancer; 2020 Apr; 20(1):336. PubMed ID: 32312286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term results of definitive chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma.
    Ochi M; Murakami Y; Nishibuchi I; Kubo K; Imano N; Takeuchi Y; Kimura T; Hamai Y; Emi M; Okada M; Nagata Y
    J Radiat Res; 2021 Jan; 62(1):142-148. PubMed ID: 33392619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of lymph node to primary tumor standardized uptake value ratio in unresectable esophageal cancer.
    Chen PJ; Yap WK; Chang YC; Tseng CK; Chao YK; Hsieh JC; Pai PC; Lee CH; Yang CK; Ho AT; Hung TM
    BMC Cancer; 2020 Jun; 20(1):545. PubMed ID: 32522275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction immunotherapy plus chemotherapy followed by definitive chemoradiation therapy in locally advanced esophageal squamous cell carcinoma: a propensity-score matched study.
    Lian HM; Wu JL; Liufu WJ; Yu TT; Niu SQ; Bao Y; Peng F
    Cancer Immunol Immunother; 2024 Feb; 73(3):55. PubMed ID: 38366287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 3-Year Overall Survival Update From a Phase 2 Study of Chemoselection With DCF and Subsequent Conversion Surgery for Locally Advanced Unresectable Esophageal Cancer.
    Yokota T; Kato K; Hamamoto Y; Tsubosa Y; Ogawa H; Ito Y; Hara H; Ura T; Kojima T; Chin K; Hironaka S; Kii T; Kojima Y; Akutsu Y; Matsushita H; Kawakami K; Mori K; Makiuchi T; Nagumo R; Kitagawa Y
    Ann Surg Oncol; 2020 Feb; 27(2):460-467. PubMed ID: 31376034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcomes of multimodal therapy combining definitive chemoradiotherapy and salvage surgery for T4 esophageal squamous cell carcinoma.
    Sugawara K; Yagi K; Okumura Y; Nishida M; Aikou S; Yamashita H; Yamashita H; Seto Y
    Int J Clin Oncol; 2020 Apr; 25(4):552-560. PubMed ID: 31828451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility of extended chemoradiotherapy plus surgery for patients with cT4b esophageal carcinoma.
    Anderegg MCJ; Ruurda JP; Gisbertz SS; Blom RLGM; Sosef MN; Wijnhoven BPL; Hulshof MCCM; Bergman JJGHM; van Laarhoven HWM; van Berge Henegouwen MI
    Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):626-631. PubMed ID: 31706717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Efficacy and Safety of Combined Chemoimmunotherapy With or Without Radiation Therapy for Stage IVB Esophageal Squamous Cell Carcinoma: A Multicenter Propensity Score Matching Analysis.
    Chen B; Chen W; Cheng Q; Zhang H; Wang B; Xu Y; Yang C; Cheng X; Wang R; Wang S; Cen P; Wang L; Dragomir MP; Zhu Y; Liu S; Xi M; Li Q; Chen B
    Int J Radiat Oncol Biol Phys; 2024 Nov; 120(4):1084-1095. PubMed ID: 38936631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcomes after non-curative endoscopic resection for esophageal squamous cell carcinoma followed by additional chemoradiotherapy.
    Cho H; Abe S; Nonaka S; Suzuki H; Yoshinaga S; Okuma K; Yamamoto S; Daiko H; Kato K; Sekine S; Boku N; Saito Y
    Dis Esophagus; 2024 Apr; 37(5):. PubMed ID: 38266034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of the nodal status on the overall survival of non-surgical patients with esophageal squamous cell carcinoma.
    Zhao Z; Zhang Y; Wang P; Wang X; Li M
    Radiat Oncol; 2019 Sep; 14(1):161. PubMed ID: 31481064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefit of chemotherapy based on platinum with definitive radiotherapy in older patients with locally advanced esophageal squamous cell carcinoma.
    Wu H; Yu Y; Zheng Q; Liu T; Wu Y; Wang Z; Zheng H; Liu L; Li J
    Radiat Oncol; 2021 Oct; 16(1):207. PubMed ID: 34717670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different prognosis of patients with esophageal carcinoma with M1a and regional node involvement.
    Chung TR; Kim JH; Lee IJ; Cho Y; Kim JW; Lee CG; Jung DH; Park JJ; Youn YH; Park H
    Dig Liver Dis; 2019 Nov; 51(11):1610-1616. PubMed ID: 31175014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of long-term outcomes between esophagectomy and chemoradiotherapy after endoscopic resection of submucosal esophageal squamous cell carcinoma.
    Tanaka T; Ueno M; Iizuka T; Hoteya S; Haruta S; Udagawa H
    Dis Esophagus; 2019 Dec; 32(12):. PubMed ID: 30980070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for locally advanced esophageal squamous cell carcinoma.
    Sasaki K; Uchikado Y; Omoto I; Arigami T; Osako Y; Noda M; Okumura H; Maemura K; Higashi R; Yoshiura T; Natsugoe S
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):581-587. PubMed ID: 30623230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction in chemotherapy relative dose intensity decreases overall survival of neoadjuvant chemoradiotherapy in patients with locally advanced esophageal carcinoma.
    Jiang L; Zhu J; Chen X; Wang Y; Wu L; Wan G; Han Y; Leng X; Zhang J; Peng L; Wang Q
    BMC Cancer; 2024 Aug; 24(1):945. PubMed ID: 39095767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involved-field irradiation in definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.
    Zhang X; Li M; Meng X; Kong L; Zhang Y; Wei G; Zhang X; Shi F; Hu M; Zhang G; Yu J
    Radiat Oncol; 2014 Feb; 9():64. PubMed ID: 24571804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical response to chemoradiotherapy in esophageal carcinoma is associated with survival and benefit of consolidation chemotherapy.
    Zhao Z; Zhang Y; Wang X; Geng X; Zhu L; Li M
    Cancer Med; 2020 Aug; 9(16):5881-5888. PubMed ID: 32627960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.